Land: Ástralía
Tungumál: enska
Heimild: Department of Health (Therapeutic Goods Administration)
levodopa, Quantity: 250 mg; carbidopa monohydrate, Quantity: 27 mg (Equivalent: carbidopa, Qty 25 mg)
Arrotex Pharmaceuticals Pty Ltd
Tablet, uncoated
Excipient Ingredients: crospovidone; magnesium stearate; indigo carmine aluminium lake; microcrystalline cellulose; pregelatinised maize starch
Oral
10 tablets, 20 tablets, 100 tablets
(S4) Prescription Only Medicine
LEVODOPA/CARBIDOPA GxP is indicated for the treatment of Parkinson's disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. LEVODOPA/CARBIDOPA GxP frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with Parkinson's disease and syndrome.
Visual Identification: Round, light blue uncoated tablets with 'C' on one side and '20' on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2018-01-11